BIOCRYST PHARMACEUTICALS INCBCRX
ASignal's systematic analysis rates BCRX as Neutral.
Reflects the latest available analysis · analyzed Oct 8, 2026
The case on BCRX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (33.6%)
- High gross and operating margins (77.39% and 45.12%)
- Positive free cash flow ($323.67M)
- Low forward P/E of 8.82x relative to growth
- High return on assets (52.86%)
- Net cash position improving with $352.57M cash and manageable debt
- Negative profit margin (-40.90%)
- Negative price-to-book ratio (-4.66x) indicating negative equity or accounting issues
- MACD below signal line suggesting bearish momentum
- Price below SMA20 and SMA50 indicating downtrend
- Limited news coverage (only 1 source: Yahoo)
- Low Reddit mentions (3) suggesting minimal retail interest
See the full verdict on BCRX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BCRX
Most investors never get a second opinion, let alone several. ASignal runs BCRX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.